#latest pharma industry magazines | Explore Tumblr Posts and Blogs

shirlleycoyle · 3 years

Text

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It

In March, David Bronner, the "Cosmic Engagement Officer" of Dr. Bronner's Magic Soaps, wrote that it was “time to publicly call out the for-profit psychedelic pharma company Compass Pathways, for their monopolistic and shady behavior.”

Bronner alleged that George Goldsmith, CEO and co-founder of mental health company Compass Pathways, had been reaching out to researchers at Oregon Health & Science University (OHSU) “in an attempt to drum up concern and mobilize opposition to implementing 109 in Oregon." (Oregon Measure 109 passed in November 2020 and outlines a path to legalizing psilocybin services in Oregon by 2023.)

This was the latest in a series of concerns voiced by various actors that Compass Pathways is attempting to exert singular control over psilocybin-assisted therapy. In 2018, Olivia Goldhill wrote in Quartz that the company had left consultants and donors feeling dismayed when it transitioned from a nonprofit to a for-profit. Since then, there have been investigations into its patents on synthetic psilocybin and questions raised about the implications of its other patent applications, which include claims on many aspects and applications of psilocybin-assisted therapy.

Bronner's statement on Goldsmith’s purported interference in Oregon highlighted what will likely be another growing tension in the mainstreaming of psychedelics more generally, outside of debates on intellectual property and ethical business models: whether psychedelics will be accessed through a medical model via Food and Drug Administration approval, or through legal and regulated access through state (or federal) laws, like the one in Oregon.

Many states are passing or considering psychedelic decriminalization or legalization. Simultaneously, FDA-approved psychedelic-assisted therapy is within reach—as close as around two years for psilocybin and MDMA. How these two paths will intersect, interact, or interfere with each other is an open question, but proponents of both worry that one might somehow harm, or even preclude the existence of, the other.

Psychedelics researchers and advocates have made great strides in regaining credibility for the drugs as subjects of research, potential treatments for a variety of conditions, and even a shrewd investment. Psychedelic companies, along with their intellectual property, are burgeoning into a billion-dollar industry. Some in the psychedelic community worry that decriminalization or state-regulated legal access to the compounds will either get left behind and forgotten or be actively prevented by those wanting to protect the for-profit industry.

Until now, what exactly Goldsmith was emailing to researchers in Oregon was unknown outside of what was outlined in Bronner's post. Through a Public Records Law request, Motherboard obtained an email that Goldsmith sent to a professor of psychiatry at OHSU on November 19, 2020. In it, Goldsmith summarized what Compass Pathways does and noted, “We are also the largest funder of psilocybin preclinical and clinical research.”

He emphasized that psilocybin therapy would be best developed in the medical model. “While we agree that there is a need for innovation in mental health care, we firmly believe that this should be developed along existing regulatory standards with FDA oversight,” he wrote. “Clearly, a majority of Oregon voters think differently.”

Email sent by George Goldsmith obtained through Public Records Request.

“Monopolistic behavior that attempts to block other entities from bringing medicines to market, or even worse, shut down Oregon’s Measure 109 model and attempt to lock up psychedelic therapy inside the FDA medical pharma model for narrow qualifying diagnoses only, is harmful to the healing we as a movement want to bring to the world,” Bronner wrote.

Goldsmith told Motherboard that hindering 109 was “not our intention ever, to be very clear." “What we saw in Oregon was simply—I said, 'Well, this is a really interesting experiment.' That's what Oregon is," Goldsmith said. "And being somebody who's trained and has a worldview like I do, when I hear the word experiment, I think about data. And so I reached out to the head of psychiatry department at OHSU and said, 'I'd love to talk.' And that was the content. It wasn't about derailing."

Goldsmith said the email was not intended as an interference in Oregon. “I just wanted to have a conversation. But I guess that’s not allowed.”

That's a pretty significant difference in interpretation of both the content and intent of one email, an example in miniature of the debate over access to psychedelics in the same way the many complaints against and defenses of Compass Pathways mirror larger issues. Is the opinion that psilocybin (and other psychedelic treatments in the future) should be kept confined to the medical system about the safety and protection of vulnerable patients, like those with treatment-resistant depression or PTSD? Or is keeping psychedelics in the medical model about forcing people to access psilocybin through a specific company’s products and services? These are questions on which people have staked out positions while seemingly ignoring the common ground between them.

The dynamics of the debate are plain enough. Goldsmith is not alone; other notable figures at for-profit psychedelic companies have publicly said that the medical model is the appropriate avenue for psychedelic-assisted therapy for mental illness. This has led community psychedelic platforms to respond in kind, saying that clinical trials and the medical model are latecomers to psychedelic knowledge, trumped by indigenous, underground, and recreational use—and are not the best way forward.

Both of these positions are extreme, though. There isn't any reason that medical and legal access necessitate a "pick or choose" situation. They can, technically, coexist to create an array of psychedelic services, available to a wide spectrum of people. This will require good faith behavior on all sides: from people accepting that others will access psychedelics in ways that may not resonate with them (like in a doctor's office), to companies staking claim in a new industry accepting that their profit margins might be smaller when there's a diversity of places to take psychedelics.

There are legitimate reasons to want certain groups of people to have as much as support and safety as possible if they want to try psychedelic-assisted therapy. This could mean directing them to the medical model outright. But there should be accountability and ethics built into whatever models come into existence—medical or legal.

The medical and legal models will share many important considerations concerning safety, ethics, and training of practitioners. They will both need to grapple with accountability and consent, and be wary of healers—medical professionals or otherwise—who veer into guru territory and make false promises and cross boundaries. Both models will need to figure out how each individual will get the support they need—before, during, and after an experience— depending on what exact issue they are seeking psychedelics for. The more minds and bodies we have thinking about these issues honestly and critically, the better.

It's not paranoia when advocates for legalized psychedelics claim that those in the for-profit space are pushing for medicalization alone. Christian Angermayer, the founder of Atai Life Sciences and a funder of Compass, said in a recent interview with Business Insider that "At Atai, we are doing medical drug development and running FDA trials. There's no consumer aspect and we want these drugs approved for medical use only."

(The unspoken irony here is that Angermayer had a life-changing psychedelic experience in a country with legal, regulated psychedelic access, yet he now insists on the medical route being the ideal option. Lars Wilde, co-founder of Compass, has referenced a similar legal psilocybin experience.)

The white paper Goldsmith attached to the email to the OHSU psychiatrist contained several mentions of the medicalization-versus-legalization issue. One of the sections is titled "Ensure that psilocybin therapy follows the evidence-based, medical route to patients, not the legalization path," with elaboration that, “There is an increasingly vocal campaign to introduce legalized psilocybin therapy through licensed facilities in the U.S. Legalization of psilocybin mushrooms in this way carries a high level of risk and would not meet the needs of the majority of patients suffering with TRD.”

On its website, Compass also writes that to make sure psilocybin therapy is safe and effective in patients, "psilocybin therapy needs to be approved by medical regulators, not legislators." (The emphasis is in the original.) Tom Insel, former director of the U.S. National Institute of Mental Health and advisor to Compass Pathways, recently told Time Magazine that he too was concerned about medical research being "overtaken by other events," like the "active movement to decriminalize psilocybin." "He worries what might happen if they become widespread outside the clinic," journalist Adam Piore wrote.

Regarding the white paper, Goldsmith said when reached for comment that the paper was referring to "well-defined, vulnerable patients who have very few care options." He further explained, "Our white paper focused on that population, and we expressed our concern that there is not enough evidence for broad public access at this point.".

But when these sentiments are combined with the alarm around the number of psychedelics patent filings in the past year, it paints the picture of a future in which psychedelics will be accessible only through a prescription and a doctor—which is not what many in the community want.

“People are worried that if psychedelics are medicalized, they'll fall into this category where their medical use will be permitted, but not if they're used outside of medicine, and that they will not be decriminalized,” said Ismail Ali, the policy and advocacy counsel at the Multidisciplinary Association for Psychedelic Studies (MAPS). “I don't think it's an irrational fear.”

In an interview with Motherboard from June, Goldsmith said that he and Compass co-founder Ekaterina Malievskaia were not “representing the medical industrial complex” but that what they have focused on from the very beginning is how to bring psychedelic therapy to a “specific group of people in a specific way"—namely, people with treatment-resistant depression who are treated by mental health professionals with their formulation of synthetic psilocybin.

“That doesn't mean that there aren’t other ways,” Goldsmith said. “It just means that what we're doing for our mission is what we're doing. It's not that it's our way or the highway.”

Goldsmith said that in his view, regulation exists to ensure that these vulnerable populations aren't taken advantage of with claims that can't be backed up by research. “They often view it as a last resort,” Malievskaia said. “And if this fails, then there's nothing else left. And so we need to be very careful how these patients are supported. We pay particular attention to how patients are prepared, how we test for safety, how we assess potential disappointment if there is a low-intensity dose or if there is no effect.” Compass' randomized controlled phase IIb study is nearly completed, and it will soon begin phase III. Alongside the nonprofit Usona Institute, they are the closest to having the data needed to apply for FDA approval for psilocybin-assisted therapy.

Malievskaia also said that in order for patients to get reimbursement through public or private health insurance, psychedelic therapy will have to go through FDA approval and enter the medical framework. This is a magnanimous goal. But as Motherboard has noted before, FDA approval doesn't guarantee insurance coverage—especially in the United States, where insurers are notoriously bad at covering psychotherapy in-network.

I asked Goldsmith, “It would be comforting for people to hear that Compass is not against legalization. Is that accurate?”

Goldsmith said, “It’s accurate. We are very articulate, I think, about the risks of legalization. But it's going to happen. I'm a big, big fan of some key principles in life. One of them is don't argue with reality. And I think this is the direction of travel. It's going to happen. I hope it happens. And fewer people are harmed than more. But there will be casualties, there are casualties everywhere. And we just take that risk.”

In response to a request for comment just before publication, Goldsmith confirmed what he told Motherboard in June. "As I’ve said before, we are not trying to stop legalisation," he said. "Voters have spoken in Oregon. I stand by my view that even in this legalisation setting, evidence matters for public safety. I think more would be better than less. That was why I reached out to Dr. Keepers. I wanted to talk with him to see what research could be done to help create this evidence base."

He also said it's likely that both models of access will coexist. "I think both legalisation and medicalisation have a responsibility to minimise risk through evidence and evidence-based therapy approaches," Goldsmith said. "And that there needs to be some way to ensure accurate and timely feedback on adverse events to ensure transparency. Unfortunately, they will happen in both settings. So, that is the basis of my comment about how we all minimize possible casualties. "

FDA-approved drug therapies can exist alongside non-therapeutic versions of the same drug. One example is omega-3 fatty acids. They can be purchased at any health food store, but they’re also an FDA-approved therapy called Lovaza.

Mason Marks, the project lead of the Project on Psychedelics Law and Regulation (POPLAR), said that THC, the active compound in cannabis, is another. It’s an ingredient in medical products, and non-FDA-approved products sold in stores with state laws regulating medical and adult cannabis use.

Now, companies that have patents on psilocybin-related inventions could, in theory, file infringement claims against people who are providing psilocybin services in states that allow for regulated access. But despite the incredible publicity around psychedelic patents being filed, Marks said he has no reason to believe they’re being filed any faster than in other fields. “Though it does seem as though they are appearing faster than they were a year or two ago,” he added.

It is common for companies to blanket a field with patents. There are companies that have hundreds of patents on a single device or medical treatment, like AbbVie, which obtained over 100 patents on its product Humira, an immunosuppressive drug. It will be important to keep an eye on the volume of psychedelic patents, and what they claim ownership over, to know if they could infringe on state-regulated access in any way.

“It's difficult to say for sure, but I would think that as the number of patents granted increases, and the number of stakeholders seeking patent protection rises, the higher the odds that infringement suits will be filed against companies and practitioners in state- and federally-regulated areas of the emerging field," Marks said.

One important legal difference will be in scheduling. The FDA approval process is different from the controlled-substance scheduling process, Marks said. In states like Oregon where psilocybin becomes regulated, it could be rescheduled on the state level but remain a Schedule I controlled substance federally until that changes via Congress or the DEA.

If psilocybin-assisted therapy became FDA-approved, it would likely only be the approved formulation and methods of administration that would be rescheduled. Non-medical, non-FDA approved psilocybin would probably remain in Schedule I.

Still, Marks said he sees no reason why state regulation of psilocybin services cannot exist alongside FDA approved medical therapies that include psilocybin. “They serve different purposes and can coexist harmoniously," he said. "Some stakeholders do not want them to coexist. But a diversity of approaches to psilocybin regulation and utilization is a good thing.”

A lot of the wariness around an insistence on the medical model comes down to questions about motive. Are FDA approval, patents, and the medical model tools to ensure safety and efficacy for vulnerable people, while being a bridge to wider access for others? Or are they tools for profit margins?

Distrust and apprehension has led to some backlash, though, toward the medical model overall. In May, Alexander Beiner, the co-founder of Rebel Wisdom, wrote an article in Chacruna posing the question, “Are Clinical Trials the Only Legitimate Path to Accessing Psilocybin?”

“We’re in the middle of a psychedelic turf war,” he wrote. “With psychedelic medicine on the cusp of going mainstream, an increasing number of players are vying for narrative control.”

Beiner was responding in part to a paper from King's College London psychedelics researcher James Rucker, who wrote that it was premature and unethical for psychedelic retreats to promise therapeutic outcomes to their visitors. “To determine whether a drug should become a licensed medicine, an objective process of scientific enquiry is required,” wrote Rucker and his co-author Allan Young. “This usually consists of a set of gold-standard clinical trials, defined by international agreement. In contrast to the history of psilocybin use, clinical trials, in their modern and robust forms, have taken place only for the past 50 years or so.”

Beiner wrote that while he agreed it wasn't right to use early data to market a psychedelic retreat, he took issue with their claim that clinical trials were the best way to usher psilocybin into the world. “Psilocybin is not a new drug," Beiner wrote. "It is a pre-existing molecule with a rich history of Indigenous use, particularly among the Mazatec, and an important history of underground and countercultural use as a spiritual sacrament or therapeutic tool."

Bia Labate, an anthropologist and executive director of Chacruna, has written similarly that “Alcohol and tobacco did not have to go through [clinical trials]. Statistically-sound clinical trials were introduced in the 1940s to ensure the safety and efficacy of new drugs and treatments. This is, of course, not the case with psilocybin or ayahuasca. Epidemiology, or the collective human experience of consumers of these substances, simply trumps clinical trials.” Beiner wrote that psychiatrists were “arguing that their profession should gatekeep therapeutic approaches using a molecule with thousands of years of existing human use.”

Beiner ended his essay by saying, “We do not have to choose between clinics and churches; we can have both. But we won’t get there by trying to defend our own turf.” But tearing down clinical trials which try to assess the safety and efficacy for specific patient groups only furthers a turf war.

Clinical trials, while admittedly imperfect, are used to test whether a substance has a benefit for a specific group of people, and what dose is safe and efficacious if so. Society has an ethical obligation to check to the best of its ability that a drug is likely to have benefit for a patient group, which is especially important when that group is a vulnerable one, like those with mental illness. No one is using alcohol and tobacco therapeutically; that's why we don't need clinical trials for those substances.

Matthew Johnson, the associate director of the Johns Hopkins Center on Psychedelic and Consciousness Research, said that most psychedelic researchers actually don’t fall into the camp of wanting to stop recreational use, and most aren’t against measures like decriminalization. “Generally, the criminalization of drugs is just a horrific idea,” Johnson said. “We have lots of public health data to support that. I don’t think my opinion on that is radical at all.”

But even if psychedelics had never been made illegal in the 1960s, we would need to develop them through medical psychotherapeutic models if we wanted to use them as medicine in some contexts, said Johnson. “You still need to work out their parameters and know how to use them effectively,” he said.

Ali thinks that clinical trials are important for policy change, but that one way to address concerns like Beiner and Labate's is to incorporate other kinds of knowledge, like Indigenous wisdom, and take them as seriously as we do RCTs—but not to say that clinical trials aren't needed. “I think to say that we shouldn't do clinical trials or shouldn't have medical access is very naive,” Ali said. “This idea that we should take one of them out to accommodate the other misses a really big point and potential for actually creating broad access."

Ben Sessa, an addiction psychiatrist and chief medical officer at AWAKN Life Science, has a more practical take: “The question of why you need clinical trials to get DMT licensed is not a very interesting question, because the simple answer is because you need clinical trials to get any medicine licensed,” he said. “As far as the FDA is concerned, LSD is no different from penicillin. It's just a drug. It has to go through phase studies to show efficacy. You have to jump through these hoops. If you collect all that data and you demonstrate safety and efficacy, it will be licensed. But it won't just because it's magical and spiritual.”

One of the other arguments in Rucker and Young's paper was that if psilocybin is offered outside of a medical context, and something goes wrong, it could undermine the credibility of the drug, and hamper researchers’ attempts at making it a legitimate medicine.

This is a semi-legitimate concern. As journalist Michael Pollan wrote in 2019, “The history of psychedelics has been marked by periods of both irrational exuberance and equally irrational stigmatization.” He cautioned that ballot initiatives “may not be the smartest way to get there. We still have a lot to learn about the immense power and potential risk of these molecules, not to mention the consequences of unrestricted use. It would be a shame if the public is pushed to make premature decisions about psychedelics before the researchers have completed their work.”

But legalization can also do the reverse. Ali said that the medical model is often the way that substances are introduced to the mainstream, and could lead to federal de-scheduling. “It’s absolutely true that if people were starting with the conversations around decriminalization or even fully legal regulated access, I don't think there would be the momentum that there is today,” he said.

“Some parts of the psychedelic community are saying, ‘It’s going to become exclusive,’” Sessa said. “That’s nuts. It's the current situation that's exclusive. Psychedelics are used by a fairly small section of people—mostly white, middle-class trustafarians who can afford to fly off to Peru and have ayahuasca from their shaman. The majority of people don't use these drugs because they're illegal and they're banned. By medicalizing them or corporatizing them or whatever you want to call it, we are increasing accessibility.”

As much excitement and focus has been on psychedelic research and the medical path, state-level psychedelic regulation has arrived, and the two need to contend with one another. The best approach to ensure a plurality of safe and ethical access points will be soliciting input from a wide variety of experts on psychedelics from all walks of life, and allowing a diversity of safe models to exist. In short, the best way for the medical and legal models to co-exist is to prove that they can—and it's Oregon we'll be looking to for a first example.

What Oregon Measure 109 outlines is legal access to "psilocybin services," which may or may not include therapy. Because of this, it’s the first example where a variety of different uses for psilocybin will try to exist in the same place, both medical and nonmedical, and the system being set up will attempt to triage people to the right level of care—a model that could be emulated on a larger scale if it works. In our Western culture, there are many people who will feel more comfortable seeking out a doctor in a clinic, a person with a medical degree. They deserve the right to do so just as much as a person who wants to seek out a shamanistic or peer-supported experience instead. Oregon’s Psilocybin Advisory Board has been reviewing evidence for the safety and efficacy of psilocybin from scientific, historical, and Indigenous sources. It published its first report in July.

“There is a tension between the idea of medical psychiatrists as the gatekeepers, and on the other extreme, that psilocybin should just be freely available,” said Atheir Abbas, a neuroscientist at OHSU who is on the Psilocybin Advisory Board but was sharing his own opinions only. “The Oregon model described in the measure is, I think, an attempt to integrate all these views.”

In Oregon, people will be able to apply for licenses to offer psilocybin services, but the bill doesn’t specify that a person will have to be an MD or even a psychologist, said Abbas. In practice, this means that there will be a lot of autonomy from individuals in the kinds of services and expertise they want to legally access. There will also be some form of systematic method built into the system whereby people with specialized and complex histories will be directed to those with the proficiency to care for them, alongside a baseline level of accountability for all.

Tom Eckert, the co-founder of the Oregon Psilocybin Society (OPS) and one of the chief petitioners Measure 109, said that’s one of the most important questions they’re working on. “What’s the best way to match providers and facilitators with clients in such a way that their needs are met and the safe spaces are created for a variety of different potential presentations?" he said. "That's a really important question, and it's not a single solution.”

Relatedly, figuring out how the licensing and training will take place, and what the training will contain, is one of the important pieces of the puzzle that the board will be hashing out over the next two years.

Sessa doesn’t think that just anyone who loves psychedelics can step into that role. “I get a lot of people writing to me saying, ‘Ben, I want to be a psychedelic therapist.’ And I say, ‘Why?’ And they say, ‘I love taking LSD.’ Well, that's not really why you should want to be a psychotherapist. You should want to be a part of this because you love working with people with depression, people with PTSD, because you've spent years training as a doctor or nurse or a clinical psychologist or psychiatrist or counselor or social worker. You understand consent and confidentiality. You understand the neurobiology. You understand all the legal aspects of it. You understand the patient clinician relationship. You are supervised by a regulatory body. Just enjoying psychedelics doesn't turn you into a clinician.”

Ali said that he thinks that the more sensitive, unstable, or complex a person’s diagnosis is, the more likely it is that they will need specialized care. The more likely someone is to have an adverse event, the better it is there are trained and specialized people present who have accountability.

“Conversely, I think a healthy, normal person—and I don't love the term normal here—but someone who may be average, does not have a diagnosis, is otherwise stable in various ways, they may not need the same kind of highly specialized care,” Ali said. If this kind of triage can be achieved, it could end up bolstering medical access, and ensuring that those people who might need extra support of the medical infrastructure find their way there.

Sessa said that he foresees a future of a variety of access points, as long as people can accept that all these points won't interfere with each other. “I can see psychedelics being available in nonclinical populations for personal growth and development and also for fun and festivals," he said. "And I can see clinics providing medical protocols managed by clinical teams for specific diagnoses. And I think people will go on to do both.”

In Oregon, Eckert said doesn’t feel a division between the medical model and legal access. “I don't participate in divisive language on any of this, because my vision has always been to see a unified platform that is nuanced, that can have flexibility within it to meet a variety of means,” Eckert said. “I'm looking at Oregon as a potential platform that addresses concerns ranging from preventive to wellness to therapeutic to medical.”

Follow Shayla Love on Twitter.

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It syndicated from https://triviaqaweb.wordpress.com/feed/

0 notes

severepeanutperfection · 3 years

Text

Terephthalic Aldehyde Market Size Industry Share, Trends, Growth, COVID-19 Impact Analysis, Opportunity Analysis and Industry Forecast, 2018–2028 | Haihang Industry Co., Ltd., Wuhai Xinye Chemical Co., Ltd., Dalian Richfortune Chemicals Co. Ltd., Alfa Aes

Overview of the global terephthalic aldehyde market with reference to the global chemicals industry

Recycle and reuse practices are impacting the sales of virgin materials, resulting into lesser dependency on volume-driven growth. New materials are showcasing potential for driving value-based growth, but chemical companies are still some time away from achieving voluminous production, while maintaining high quality at the same time. Barring few exceptions, a majority of players are still prioritizing short-term volume growth over long-term value growth. Pressure on improving bottom-line is influencing manufacturers to improve efficiency and reduce operational costs. The impact of value-driven growth may not be visible in the short-term, but long-term outlook remains in favor of a balanced approach between value and volume.

Manufacturers are under increasing pressure to incorporate digital solutions in their offerings. Forward-thinking manufacturers are investing in technology to reduce human interference and streamline key operational aspects such as ordering and shipping. Resonating its influence over every industry, Internet of Things (IoT) has the potential to transform and disrupt the chemical sector. Connectivity through IoT devices is gaining traction, whereas product-level sensors on dispensing equipment and barrels are helping manufacturers track their consignments digitally. Through assessment of long-term benefits, chemical companies are capitalizing on digitization by adopting digital platforms & processes that eliminate human error in profit-associated operations.

Visit For Sample>>https://www.futuremarketinsights.com/reports/sample/rep-gb-487

Manufacturers continue seeking low-priced feedstock in a bid to marginally reduce pre-production costs. Industry leaders are joining forces to replace fossil fuel-derived feedstock with bio-based alternatives. However, concerns related to producing affordable and sustainable feedstock at mass scale remains a challenge. Access to quality and affordable feedstock will continue to remain a focus area for manufacturers. Chemical manufacturing processes are running on limited energy, while volume of feedstock is getting stranded at ports as disapproval from import authorities keeps disrupting supply chains in sectors, such as oleochemicals and petrochemicals industries.

Chemical manufacturers have promised support and adherence to governments & regional authorities that are committing towards green, sustainable initiatives. Development of bio-alternatives is gaining momentum. Research & academic institutes are teaming up with manufacturers to formulate sustainable substitutes for commonly-used chemical substrates. Many companies are keeping a close eye on advancements in “green chemistry.” Shift towards eco-friendly chemicals will gain momentum in the future on the back of government regulations and end-user preference. Rising costs of fossil fuels will also instrument the upsurge for sustainable chemicals manufacturing.

List of factors tracked in the Chemicals and Materials Market Report

Chemical Industry Value Add

Chemical Sales

Per Capita Consumption

Standard Capacity Factors

Plastics Consumption Outlook

Glass Consumption Outlook

Policies and Regulations

Historical growth of top players

Growth in associated markets

Net trade scenario

Apparent production capacity

For any queries linked with the report, ask an analyst >>https://www.futuremarketinsights.com/ask-question/rep-gb-487

Research Methodology

FMI utilizes robust methodology and approach to arrive at market size and related projections. The research methodology for this report is based on 3 dimensional model. We conduct about 45-60 min duration detailed interviews with product manufacturers; apart from this we also collect market feedback from industry experts. To validate this data, we interact with senior panel members having more than 10 years of experience in relevant field. The panel members help in validating the findings and fill the gaps if any. In addition, we leverage on our existing pool of information, paid database and other valid information sources available in public domain. Usually industry interactions extend to more than 50+ interviews from market participants across the value chain.

Data Collection

FMI collects data from secondary sources including company annual reports, association publications, industry presentations, white papers, and company press releases apart from these we leverage over paid database subscriptions and industry magazines to collect market information and developments in exhaustive manner. After being done with desk research, detailed questionnaire and discussion guide is formulated to initiate primary research with key industry personnel; the discussion aims at collecting key insights, growth perspectives, prevalent market trends and quantitative insights including market size and competition developments. Both of these research approaches help us in arriving at base year numbers and market hypothesis.

Data Validation

In this phase, FMI validates the data using macro and micro economic factors. For instance, growth in electricity consumption, industry value added, other industry factors, economic performance, growth of top players and sector performance is closely studied to arrive at precise estimates and refine anomalies if any.

Buy Report >>https://www.futuremarketinsights.com/checkout/487

Data Analysis and Projection

Data analysis and projections were made based on proprietary research frameworks and statistical analysis, which was further validated from industry participants. These frameworks include Y-o-Y growth projections, macro-economic factor performance, market attractiveness analysis, key financial ratios, and others.

For public companies we capture the data from company website, annual reports, investor presentations, paid databases. While for privately held companies, we try to gather information from the paid databases (like Factiva) and based on the information we gather from databases we estimate revenue for the companies. In addition, the team tries to establish primary contact with the companies in order to validate the assumptions or to gather quality inputs.

Standard Report Structure

Executive Summary

Market Definition

Macro-economic analysis

Parent Market Analysis

Market Overview

Forecast Factors

Segmental Analysis and Forecast

Regional Analysis

Competition Analysis

Target Audience

Production Companies

Suppliers

Channel Partners

Marketing Authorities

Subject Matter Experts

Research Institutions

Financial Institutions

Market Consultants

Government Authorities

Market Taxonomy

The global terephthalic aldehyde market has been segmented into:

By Application

Optical Brightener

Polymers

Pharmaceutical Intermediates

Others

By Grade

Pharma/Super Grade

Technical Grade

Explore Wide-ranging Coverage of Various Reports

Amines Market FMI’s analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region.

Firearm Lubricants Market Find insights into global market scenario and segmentation on the basis of ingredients, application, source and region.

Specialty Silica Market FMI’s report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period (2019-2029).

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: [email protected] For Media Enquiries: [email protected] Website: https://www.futuremarketinsights.com

0 notes

pharmaphorumuk · 3 years

Text

Research predicts the post-COVID landscape for HCP engagement

IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes.

This article appears in full in Deep Dive: Market Access 2021. Read a preview below:

Recent ChannelDynamics data from IQVIA shows that while there has been a marked positive change in HCPs’ views of remote rep platforms over the past 12 months, there has not actually been much change in their views of face-to-face engagement, and there has only been a small positive change for telephone, email and automated online detailing.

“Physicians are not saying that their views of in-person interactions have gone backwards,” says Liz Murray, global lead, HCP Engagement Centre of Excellence, Contract Sales & Medical Solutions, at IQVIA. “That’s a really interesting point to keep in mind.”

Murray also notes that HCPs’ attitudes to engagement have varied wildly between different countries both before and during the pandemic.

“Countries like the UK saw a huge slowdown in HCP engagement over COVID, supplemented by remote engagement, and things haven’t really changed in the last 12 months,” she says. “Meanwhile, countries like Italy are now seeing a shift back towards face-to-face engagement – almost to pre-pandemic levels – while countries like Spain sit somewhere in-between.”

These statistics might go against conventional wisdom that digital dominance is here to stay, but Murray says that examples like Italy show that future strategies will not be a question of digital versus face-to-face.

Instead, companies will need to consider how those channels can be blended to fit different HCPs and environments.

“There will certainly be plenty of examples of standalone digital engagement, but we’re also going to see reps’ roles evolving into a more multichannel-orientated way of working.”

She says that this will ultimately mean reps are talking to HCPs in a “more connected way”.

“The tradition of reps just pushing key messages is probably not going to work anymore. HCPs want content with true added-value; they want it to be solution-focused and considerate of what they actually want and need.”

But not all companies are as far along this path as they could be.

“The pandemic has been the motivation missing for the past 15 years, forcing the industry to look at alternative ways of doing things, but the speed at which a company actually changes is dependent on how forward-thinking they were beforehand. For example, did they already have e-consents in place, or were they completely reliant on face-to-face and are now having to start from scratch?”

• Read the full article in pharmaphorum’s Deep Dive digital magazine

The post Research predicts the post-COVID landscape for HCP engagement appeared first on .

from https://pharmaphorum.com/views-analysis-market-access/research-predicts-the-post-covid-landscape-for-hcp-engagement/

0 notes

pharmafocusasiamagazine · 2 years

Text

Role of miRNAs in Neurodegeneration Diseases

Bidisha Roy, Department of Biological Sciences, Rutgers University shared her views with Pharma Focus Asia.

This article highlights the relevance of studying brain-enriched miRNAs, the mechanisms underlying their regulation of target gene expression, their dysregulation leading to progressive neurodegeneration, and their potential for biomarker marker and therapeutic intervention. This article has been written to emphasize ways for the effective diagnosis and prevention of these neurodegenerative disorders in the near future.

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic lateral sclerosis (ALS) are a group of age-related progressive disorders initiated by the neuronal loss that eventually leads to cognitive and movement disorders. These diseases are thought to be caused by alterations to protein-coding genes. Non-coding RNAs participate in translational regulation and comprise 95 per cent of total human cellular RNAs.

Read More: https://www.pharmafocusasia.com/research-development/role-mirnas-neurodegeneration

#Role of miRNAs in Neurodegeneration Diseases #Neurodegeneration Diseases #pharma magazine #pharma industry updates #latest pharma magazines #pharma articles

0 notes

louislehot03 · 3 years

Text

The Art of the Exit – What Happens to Startup Culture After a Merger or Acquisition?

The art of M&A includes integrating cultures

This article was originally published at Westlaw.com on April 12, 2021.

Successfully selling your startup to a larger player or succeeding in helping your big tech or big pharma company buy a hot new startup on the cutting edge is a barometer of success in the global Silicon Valley in 2021. Mergers and acquisitions are a common part of the corporate life cycle, especially in the tech and life sciences industries, where many established companies expand into new markets by buying startups that are innovating in emerging fields. But integrating a tiny startup into a much larger company can be challenging, typically because the larger company operates with more process and structure, and the startup operates based on deeply held values. A hallmark of successful combinations is forming a common view on culture and shared values.

What is culture? In our work on behalf of dozens of startups, emerging growth companies, and large global companies, we see culture from the inside and the outside. We see brand-new and long-standing, largely implicit, shared values, beliefs, and assumptions that influence behavior, attitudes, and direction. In other words, corporate culture is how employees as a group think and act, and sometimes, cultural differences can become severe enough to derail integration.

As a simple example, a small startup might have Ping-Pong tables in the break room and provide sushi lunches for everyone on Fridays. These niceties may be less likely to persist at a large company with a stricter culture, so a merger between the two corporations could lead to disagreements between "fun" and "serious." While disputes over perks might frustrate employees, cultural differences can be much more serious, such as how leaders make decisions or how managers relate to their subordinates.

The first step to reconciling cultural differences is identifying them. Sometimes, the most important bridges between cultures are outsiders because they have no stake in whose point of view prevails. Consider engaging key people from both companies to work on the cultural differences and decide how to reconcile them. This cultural integration team should hash out the key differences, what can be kept, and what needs to be changed.

Early in the integration process, have the team start identifying how each company operates. Management style is an important aspect, but you should also consider how employees interact with each other and their managers. Try to identify the implicit assumptions that both companies have. Once you have identified these assumptions, determine which ones align with the combined company's goals and vision. Keep what will help. Change what will not.

Throughout the process, make sure that the integration team communicates clearly what is happening and why. But do not simply dictate what changes will be made. Genuinely ask for input from employees at both companies and keep them in the loop. Many people are wary of change, but transparency and being willing to listen will help prevent alienating anyone, which will encourage employees to stay.

When cultural integration is handled well, the combined company benefits from the strengths of the original organizations. McKinsey points out that “A merger provides a unique opportunity to transform a newly combined organization, to shape its culture in line with strategic priorities, and to ensure its health and performance for years to come.”

Seize the opportunity and build a new corporate culture that benefits everyone involved. Combining a company with another venture provides a breath of fresh air for both talent and technology. But it’s not easy to fusion two companies.

Ideally, the integration process will begin even before the deal is announced. Once announced, identify things that must be done prior to close and make many of the significant decisions early on so that you can act quickly on the day you close.

New Leaders, New Vision

A new organization should be designed around the deal vision for the combined company and include people from both organizations who are the best athletes for the position. Be aware that once a company announces its intent to merge, top customers and key employees will be actively poached by your competitors. This is why a company going through a merger or acquisition faces a real risk of losing key talent. Mergers introduce a period of instability. Communicating around a new combined leadership team quickly, and filling in joint teams, may help stem the tide of a potential brain drain. Delay can lead key players to depart before the deal is closed.

One Company, One Culture

Successfully combinations take the best elements of two cultures and make them one. While each buyer and seller will start a process with a distinct culture and set of values that govern how its people interact day today, the combined company should commit to the vision and culture you want to see emerge from the integration. Once it achieves consensus on these values and culture, then it can aggressively put them into practice. Company leaders should model the desired behaviors and transparently.

Incentivizing New Behaviors

To retain top talent following a merger or acquisition, reconsidering incentives and compensation is critical. Identifying the key contributors, both historically and in the future, and paying them for the very same, has become a science. This is important not only for leaders but for rank and file.

During a significant acquisition, the company asks a lot from its leaders, while those leaders' prospects may be uncertain. Pay for performance. There is a simple formula: historical contribution gets cash, while future contribution should get equity. Compensation is a powerful tool in both the pre-close execution phase and post-close integration. Retention awards and transition incentives are typically used to supplement other incentive or severance programs that might already be in place. Retention awards are usually vested at specific milestones, while transition incentives are often vested based on achieving specific objectives. Together they are a powerful combination.

Post-closing considerations may involve a new program altogether for the new business and evaluating whether executives are adequately staked in the new organization. This includes aligning pay levels, bonus plan metrics and design, and long-term incentive vehicles and vesting with the latest business objectives.

It is essential to look at the company's payment history and approach and whether that reflects the new businesses' strategic objectives. If pay changes are warranted, time will allow for assessing whether executives can handle the increased responsibilities and help manage the organization's overall cost impact.

In designing culture and values, rewarding past performance and incentivizing accountability for future performance metrics will govern behaviors going forward. Designing success is partly a form of art and partly science and execution.

About the Author:

Louis Lehot

Louis Lehot is an emerging growth company, venture capital and M&A lawyer at Foley & Lardner in Silicon Valley. Louis spends his time providing entrepreneurs, innovative companies, and investors with practical and commercial legal strategies and solutions at all stages of growth, from garage to global. He focuses his efforts on technology, digital health, life science and clean energy innovation. Louis’s clients are public and private companies, financial sponsors, venture capitalists, investors and investment banks, and he has helped hundreds of companies at formation, obtaining financing, solving governing challenges, going public and buying and selling. Louis is praised by clients, colleagues and industry guides for his business acumen, legal expertise and leadership in Silicon Valley.

Connect with Louis Lehot:

Website: Louis Lehot

LinkedIn: Louis Lehot

Facebook: Louis Lehot

Twitter: Louis Lehot

Instagram: Louis Lehot

YouTube: Louis Lehot

Vimeo: Louis Lehot

Pinterest: Louis Lehot

Ello: Louis Lehot

Magazine Xpert: Louis Lehot

Crunchbase: Louis Lehot

Muckrack: Louis Lehot

Anchor.fm: Louis Lehot

Ideamensch: Louis Lehot

Chief Executive: Louis Lehot

Data Driven Investor: Louis Lehot

Good Men Project: Louis Lehot

Speaker Hub: Louis Lehot

Read the Articles written by Louis Lehot:

Louis Lehot- What to expect for seed and pre-seed stage financing in 2021

Louis Lehot- A Brief Legal Guide To Buying And Selling Shares Of Private Company Stock

Louis Lehot- The IPO Markets Are Changing, And So Is The Lock-up Agreement

Louis Lehot- What are SPACs, and how they are different from IPOs?

Louis Lehot- L2 Counsel Represents AgTech Leader FluroSat In Dagan Acquisition

Louis Lehot- Considering Selling Your Company? Be Clear on Your Fiduciary Duties

Louis Lehot- Incentivizing With Stock Options: What Your Startup Needs To Know About ISOs, NSOs And Other Parts Of The Alphabet Soup

Louis Lehot- Ready To Sell Your Startup In 2021?

Louis Lehot- The State Of The Acqui-Hire In 2021: The Good, The Bad, The Why And What’s Next

Louis Lehot- Leaving Your Job? Don’t Forget Your Stock Options…

Louis Lehot- A Short Primer for Startups on Local Labor and Employment Law Compliance

Louis Lehot- How To Clean Up A Corporate Mess

Louis Lehot- Calculating And Paying Delaware Franchise Taxes — Startups Need Not Panic

0 notes

magazinesubscriptions11 · 1 year

Text

𝐏𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐚𝐥 𝐈𝐧𝐝𝐢𝐚, 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥 𝐦𝐚𝐠𝐚𝐳𝐢𝐧𝐞

Pharma Industrial India, professional magazine for the Pharma and Biopharma Industry Suppliers & Lab Technology, The magazine and the website cover all the latest news and happenings in the Indian pharmaceutical and pharmabiotech industry and related sectors

0 notes

electronicemergingtrends · 3 years

Text

Blood-Brain Barrier (BBB) Market Research Report By Type, Application and Regions 2021-2027

The Global Blood-Brain Barrier (BBB) Market Size, Share & Growth Analysis By Application (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer), By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing Permeability, Passive Diffusion, Others), By End-Use (Hospitals, Surgical centers, Research Institutes, Others) And Regional Forecast, 2021-2027 This research & consulting report doles out information about the global Blood-Brain Barrier (BBB) market. The forecast period of the market extends till 2027, while commencing in 2020. The report sheds light on various key insights & trends that have occupied center stage & drawn the attention of end-users. The Blood-Brain Barrier (BBB) industry is witnessing impressive expansion at present, having logged double digit CAGRs in the past.

Read more: https://www.eternityinsights.com/report/blood-brain-barrier-bbb-market

The report alludes to the Blood-Brain Barrier (BBB) market as a lucrative sector. This sector is slated to generate substantial revenues during 2021 to 2027 (forecast period). The analytical report highlights data & overview regarding the size, shares, & demand of Blood-Brain Barrier (BBB). Several other factors have had a positive or negative impact on the industry, all of which have been laid out in details.

Pros & Scope of The Report

The said factors comprise drivers, novel prospects, hindrances, and other vital characteristics of the market. Investments by rivals into Blood-Brain Barrier (BBB) products have catapulted the market into limelight & have stoked its demand, globally.

Few among other key aspects that find a mention; encompass the industry segments, predictions, & size and shares for 2021 to 2027. Besides these; the report narrows down on the innovative trends & technological developments, expansion strategies of key players, and regional statistics.

Some of the companies for Blood-Brain Barrier (BBB) market are:

· 2-BBB

· 2X Oncology

· 4P Therapeutics

· AB Science

· Abbott

· AbbVie

· Ablynx

· AC Immune

· ACADIA Pharmaceuticals

· Accera

· Acelot

· Acorda Therapeutics

· Actinogen Medical

· Acumen Pharmaceuticals

· Adamas Pharmaceuticals

· Addex Therapeutics

· Advanced Accelerator Applications

· Advanced BioHealing

· Aeolus Pharmaceuticals

· Aescap Ventures

· Aestas Pharma

· Affectis Pharmaceuticals

· AFFiRiS

· Agate Medical Investments

· AgeneBio

· Agoranov

· AiCuris

· Aix-Marseille University

· Alaska Permanent Fund

· Alcyone Lifesciences

· Alector

Request Free Sample: https://www.eternityinsights.com/request-a-sample/34809

· Alkahest

· Allergan

· Allinky Biopharma

· Alnylam Pharmaceuticals

· Alzinova

· AlzProtect

· AMAbiotics

· Amarantus Therapeutics

· American Cancer Society

· American Life Science Pharmaceuticals

· Amgen

· Amylyx Pharmaceuticals

· Anavex Life Sciences

· Angiochem

· Antea Group

· Antoxis

· Aphios

· ApoPharma

· APRINOIA Therapeutics

· Araclon Biotech

· Arbor Pharmaceuticals

· ARCH Venture Partners

· Archer Pharmaceuticals

· ArmaGen

· ARMGO Pharma

· ArQule

Ask For Discount: https://www.eternityinsights.com/ask-for-discount/34809

· Array BioPharma

· Arrien Pharmaceuticals

· Arrowhead Pharmaceuticals

· Artenga

· Asceneuron

· ASCIL Biopharm

· ASEBIO

· Astellas Pharma

· AstraZeneca

· Atlas Venture

· aTyr Pharma

· Aurin Biotech

· Ausio Pharmaceuticals

· Autifony Therapeutics

· Avanir Pharmaceuticals

· Axon Neuroscience

· Axovant Sciences

· Axsome Therapeutics

· AZTherapies

· Bach Pharma

· Baillie Gifford

· Baxter Healthcare

· Bayer

· BBB Therapeutics

· BDC Venture Capital

· BELLUS Health

· BenevolentAI Bio

· Ben-Gurion University

· BGN Technologies

· BIAL Group

· BIND Therapeutics

· BioAdvance

· BioAgilytix

· BioArctic

· biOasis Technologies

· Biocat

· Biocrea

· BioElectronics

· Biogen

· Biohaven

· BioLineRx

· BioMarin

· Bionomics

· Biotie Therapies

· Biovista

· BlueRock Therapeutics

· Boehringer Ingelheim

· Boehringer Ingelheim Venture Fund

· Boston Scientific

· BpiFrance

· Brain Biomarker Solutions

· Brains for Brain Foundation

· BrainsGate

· BrainStorm Cell Therapeutics

· BrainVectis

· BrainX

· Brisco Capital Partners

· Bristol-Myers Squibb

· Britannia Pharmaceuticals

· Broad Institute

· CAAP Creation

· Caixa Capital Risc

· Cantabio Pharmaceuticals

Enquiry Before Buy: https://www.eternityinsights.com/enquiry-before-buying/34809

· Capo Therapeutics

· Carna Biosciences

· CarThera

· Cellix Bio

· Cenna Biosciences

· CENTOGENE

· Cerecin (formerly called Accera)

· Cerecor

· CereSpir

· Cerevance

· CHA Biotech

· Changchun Huayang High-tech

· Chaperone Therapeutics

· Chipscreen

· Chronos Therapeutics

· CinnaGen

· Cipio Partners

· Clera

· Clevexel

· CNRS Innovation

· Cobra Biologics

· Cogentis Therapeutics

· Cognition Therapeutics

· Cognosci

· Collaborative Medicinal Development

· Columbia University

· Contera Pharma

· CoPlex Therapeutics

· Corium International

· Cornell University

· Cortexyme

· Cortice Biosciences

Read more: https://www.eternityinsights.com/report/blood-brain-barrier-bbb-market

· Corvitex

· Crinetics Pharmaceuticals

· CuraSen Therapeutics

· Curemark

· Cyclenium Pharma

· DAE HWA Pharmaceutical

· Daewoong Pharmaceutical

· Dainippon Sumitomo Pharma

· Dart Pharma

· Debiopharm

· Deciphera Pharmaceuticals

· DEKK-TEC

· DelMar Pharmaceuticals

· Denali Therapeutics

· DermaXon

· Dexcom

· Domain Therapeutics

· Dong-A ST

· Edunn Biotechnology

· Eight Roads Ventures

· EIP Pharma

· Eisai

· Elan Pharmaceuticals

· Eli Lilly

· Elron Electronic Industries

· EMD Serono

· EMulate Therapeutics

· EnhanX Biopharm

· Enterin

· E-Scape Bio

· Ethris

Ask For Discount: https://www.eternityinsights.com/ask-for-discount/34809

More Inputs & Objectives

The manner in which nascent & local competitors stack up against prominent players, hogs the spotlight. Novel products & services, coupled with the monetary shares of eminent competitors and the SWOT analysis unveil the complexities of the global industry size.

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends from 2021 to 2027 in each of the sub segments. For the purpose of this study, Eternity Insights has segmented the global Blood-Brain Barrier (BBB) market on the basis of SMEs, large enterprises, others and region:

Blood-Brain Barrier (BBB) Market, By Application

· Alzheimer’s Disease

· Epilepsy

· Parkinson’s Disease

· Multiple Sclerosis

· Hunter’s Syndrome

· Brain Cancer

Blood-Brain Barrier (BBB) Market, By Type

· Bispecific Antibody RMT Approach

· Trojan Horse Approach

· Increasing Permeability

· Passive Diffusion

· Others

Enquiry Before Buy: https://www.eternityinsights.com/enquiry-before-buying/34809

Blood-Brain Barrier (BBB) Market, By End-User

· Hospitals

· Surgical Centers

· Research Institutes

· Others

Blood-Brain Barrier (BBB) Market, By Regional Outlook

· North America

· U.S.

· Canada

· Mexico

· Europe

· Germany

· UK

· France

· Rest of Europe

· Rest of the World

· Latin America

· Middle East & Africa

· Asia Pacific

· China

· Japan

· India

· Rest of Asia Pacific

Research Methodology

Research methodology is an integral component of any kind of high-level market research. It entails evaluation by expert panels, research on secondary & primary levels, checks on quality, & testing on completion. Secondary research deeply focuses on the whys, whos, wheres, whens, & hows and caters to answering the strictly consumer-centric base of people.

Some other secondary research sources comprise governmental affiliations & blogs, business magazines, and industrial journals. Primary research includes face-to-face & telephonic interviews with industry experts. It is comparatively more detailed & lays stress on unprejudiced opinions about the products & services.

Primary research findings cement secondary research & help end-users & businesses get a better hang of various markets. It is a well-established fact, though, that research methodology is best implemented through the mixed execution of its aforementioned procedures.

What Does the Report Offer?

· A breakdown & profiling of the qualitative & quantitative analysis of the industry.

· An in-depth overview of the segments & sub-segments of the industry, unlocking their shares and positions.

· Data on market players & their growth strategies.

· Industry outlook, via value chains.

· Mergers & acquisitions, the SWOT analysis of prominent competitors, and high-tech product launches.

· Drivers, hindrances, factors that positively & negatively impact the market, and new opportunities.

· Crucial information and actionable insights, enabling businesses to widen their traction & to have an edge over others.

· Regions into which the global market is fragmented and the reigning regional markets & their respective shares & revenues.

· Analytical support on the purchases made/orders passed.

Request Free Sample: https://www.eternityinsights.com/request-a-sample/34809

Other Vital Points That Are Covered

· The impact of Covid-19 on each of the segments of the Blood-Brain Barrier (BBB) market.

· The suppliers, manufacturers, raw materials, dominating players, etc.

· Key regional contributors & their shares in the past and the future.

· Evaluation of most of the important countries within particular regions in view of their revenues, supplies, supremacy, business returns, & consumption volumes.

· Advanced technologies that surround the market and comprehensive outlook on industry applications, products, end-users, & regions.

· Technological & statistical data to cater to the demands of businesses, shareholders, & companies and to help them grow further.

· Comparison of competitors against other players and the dominant companies during the forecast period. Strategies employed by reigning stakeholders to gain further traction & to generate higher revenues.

· End users that are ahead in the rat race and the positive factors that influence those end users.

· Applications that should come out on top by the end of the forecast period.

· Products that occupy the maximum shares and the drivers behind those products.

· Factors that bode well for the Blood-Brain Barrier (BBB) market and a mention of other industries that are closely associated with the Blood-Brain Barrier (BBB) market.

· Regions that open the floodgates to higher investments and greater opportunities.

· Records of the market sales, volumes, CAGRs, & shares.

The market report also brings to light major opportunities and untapped geographies. It is more like a blend of customized research documents & conventional reports. Besides informing buyers about the pros & cons of direct and indirect sales channels, the analysis exhibits illustrations & graphical representations of industry growth and the innovative trends within the industry.

About Us:

Our reputed “market research & consulting” portal, “Eternity Insights” publishes industry/market reports, equity & financial data, and analytical research reports. We focus on almost all industries and deeply examine their segments & sub-segments. Our platform further probes the market revenues, ongoing trends, driving/preventive factors of the industries, key categories & sub-categories, competitive overview, etc.

Via its innovative approaches, the firm analyzes data and aims to meet the requirements of its customers. We assist clients with setting up their businesses, promoting their products & services, and informing them about mergers & acquisitions. Our team studies market reports in details & roles out consulting services to the customers for their expansion.

Address: Eternity Insights

Office No.A-3/308, 3rd Floor, Premnagar Complex,

Thane, Mumbai, MH, 400605, India.

Phone: +91 8459596463

Email: [email protected]

#Blood-Brain Barrier (BBB) Market Share #Blood-Brain Barrier (BBB) Market Size #Blood-Brain Barrier (BBB) Market Trends

0 notes

ericvick · 4 years

Photo

Curaleaf expands its cannabis empire to Europe with a $286 million deal

Benzinga

Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of March 1st – 7th, 2021. Without further ado, let’s get started. * Yahoo Finance readers, please click here to view the full article. 10. Creso Pharma: A Global Cannabis Powerhouse in the Making With Canada Currently the Only Major Country at the Moment to Allow Recreational Cannabis Nationwide and Mexico and the U.S. Expected to Join Their Neighbour to the North By the End of 2021, Much of the Attention on the Cannabis Industry is Focused on the Americas These are no doubt groundbreaking advancements, but in an emerging industry in its infancy, it’s just the beginning. As the push for legalization in the U.S., Mexico, Latin America, Europe, the Middle East and Asia-Pacific intensifies, Cannabis is ultimately going global. One company that is focused on exploring these international opportunities is Creso Pharma (OTC: COPHF). Based in Australia, and with operations around the world, Creso has emerged as a global cannabis industry leader. READ FULL CRESO PHARMA ARTICLE 9. Local Activists in Washington State Push For Psilocybin Decriminalization Voters in Spokane, Washington Could Make the City One of the Latest to Decriminalize Psilocybin Mushrooms Under a Proposed Ordinance That Was Recently Filed By Local Activists The initiative, which was introduced by the group Decriminalize Spokane, would make enforcement of laws prohibiting the personal possession, cultivation and limited distribution of Psilocybin for adults 21 and over among the city’s lowest priorities and would further ban officials from using “any city funds or resources to assist in the enforcement of laws imposing criminal penalties for the use, possession, transportation, cultivation, or distribution of psilocybin mushrooms.” READ FULL WASHINGTON PSILOCYBIN ARTICLE 8. The Race to Patent Psychedelics is Just Getting Started Psychedelics Now Appear in Patent Applications for Philip Morris E-Cigarettes, Periodontal Disease, Hair Loss, Weight Loss, and Food Allergies Patent announcements are hard to miss in the Psychedelic field these days. Most recently, as Troy Farah wrote in Future Human, the biotech startup CaaMTech was granted a patent for the combination of Cannabis and Psilocybin. A patent application from mental health company Compass Pathways (NASDAQ: CMPS) garnered attention for including claims on very basic elements of psychedelic psychotherapy—from holding hands to using soft furniture. READ FULL PSYCHEDELIC PATENTS ARTICLE 7. Cannabis-Infused Beverage Sales Up 40%, Helped By Consumers Seeking Convenient Products Marijuana Beverage Companies, For Example, Have Been Cashing in on Health-Related Trends Such as Dry January, When Alcohol Drinkers Abstain for the Month and Look for Alternative Ways to Relax Sales of cannabis-infused beverages were up 40% last year, as companies sought to capitalize on new marijuana consumers seeking a familiar form of consumption and those looking for an alternative to alcoholic drinks. READ FULL CANNABIS BEVERAGES ARTICLE 6. Study Finds Ketamine Can Help Patients Manage Depression and PTSD On March 2, Associate Professor Monnica Williams, Who is Also the Canada Research Chair for Mental Health Disparities at the University of Ottawa’s School of Psychology, Led an Online Seminar Entitled, “Psychedelics, Therapies, Research, and Training” During the seminar, Williams explained how Ketamine, a dissociative drug that can distort one’s environment and thoughts, can help patients overcome anxiety, depression, and post-traumatic stress disorder (PTSD). In her study, Williams wrote that ketamine can reduce depressive symptoms in patients and these benefits can last for nearly two weeks. Also in this study, Williams explains why ketamine alleviates symptoms of post-traumatic stress disorder (PTSD). Ketamine, “produces [an altered] state of consciousness, promotes relief from negativity, [and produces] an openness to new perspectives.” READ FULL KETAMINE ARTICLE 5. Mexican Lawmakers Circulate Amended Marijuana Legalization Bill That’s Set For a Vote on Monday Lawmakers in Mexico’s Chamber of Deputies Are Finally Set to Take Up a Bill to Legalize Marijuana Nationally in the Coming Days, But the Proposal Has Recently Been Subject to Several Significant Revisions Since Being Approved By the Senate Last Year First, a joint hearing of the chamber’s Health and Justice committees will take place on Monday, and a vote in the full chamber is expected the following day or on Wednesday. Advocates have been eagerly awaiting the introduction of new language, hopeful that it would address certain concerns with the Senate proposal, and now they’re getting details about what is being changed by the joint panels. READ FULL MEXICO CANNABIS ARTICLE 4. Peter Thiel-Backed Psychedelics Firm Hits $2-Billion Valuation Atai Life Sciences is Gearing Up for a Potential U.S. IPO as Soon as the Second Quarter, Sources Say Atai Life Sciences, a German startup looking into ways of using Psychedelic substances to treat mental health disorders, has been valued at about US$2 billion in a funding round ahead of its potential listing, people familiar with the matter said. Berlin-based Atai plans to hire Credit Suisse Group AG and Citigroup Inc. for a potential U.S. initial public offering that could take place as early as the second quarter, the people said, asking not to be identified because the information is private. READ FULL ATAI ARTICLE 3. With Marijuana the Hot Theme of 2021, Here’s Why Red White & Bloom Could Be One of the Cannabis Sector’s Top Performers Anyone Remotely Familiar With Cannabis Investing Has Heard of High Times Magazine, However, Many Are Still Unaware of the Rising U.S. Marijuana Stock That Owns the Rights to High Times Branded Assets in Key U.S. Markets Red White & Bloom(OTCQX: RWBYF), a rising U.S. Multi-State Operator (MSO) with a growing American footprint that now includes California, Arizona, Michigan, Illinois, Oklahoma, and Massachusetts, has until now largely flown under most investors’ radar. READ FULL RWB ARTICLE 2. Will Hawaii Pass a Psilocybin Legalization Bill? Senator Chang Makes a Strong Case Last Month, a Group of Hawaiian Legislators Introduced a Bill That Would Legalize and Regulate Psilocybin, the Active Compounds in “Magic Mushrooms” “The reason I wanted to introduce this measure is that, as you know, in the 2020 election, a number of jurisdictions across the country, including Oregon, Oakland, Sacramento, Denver, Somerville, have moved forward with different legislation on Psilocybin and further research and application of its mental health properties. And I believe that Hawaii should be part of that movement,” said Hawaii Senator Stanley Chang, one of the bill’s proponents. READ FULL HAWAII PSILOCYBIN ARTICLE 1. Canopy, Creso, and Celebrities Including Martha Stewart Capitalize on Growing Pet CBD Industry While Developments in the Diversification of CBD Products Have Been Mainly Targeted Towards Humans, Celebrities and Companies Like Canopy Growth and Creso Pharma Are Cashing in on the CBD Industry Targeted Specifically to Our Furry Friends In addition to her best-selling Martha Stewart CBD gummies, Stewart has made the foray into CBD for pets, which is Stewart says is “a very fast-growing category,” when she appeared on Fox Businesses Mornings with Mindy on Monday, “That industry is going to be worth $10 billion by 2023, it’s estimated,” the popular house and home guru stated. Stewart has partnered with Canopy Growth (NYSE: CGC) to produce a variety of CBD-infused chews targeted at anxiety, wellness and mobility help for pets. Bruce Linton, the founder and former CEO of Canopy Growth, is now a strategic advisor for Creso Pharma (OTC: COPHF), which has been researching pet products in Switzerland. Linton called cannabinoids for pets a “big underserviced serious market”, noting that Creso’s focus on research and development is what sets their pet products apart, with other companies, notably in North America, putting “the marketing brochure before the effort of doing the work.” READ FULL PETS CDB ARTICLE Photo by Rick Proctor on Unsplash See more from BenzingaClick here for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

#Cannabis #Curaleaf #deal #empire #Europe #Expands #million

0 notes